Change in Systemic Medication and its Influence on Intraocular Pressure - Results From the Gutenberg Health Study.
Laspas Panagiotis, Hartmann Alica, Scholz Ida, Hoffmann Esther Maria, Khawaja Anthony P, Lackner Karl Johannes, Münzel Thomas, Kerahrodi Jasmin Ghaemi, Schmidtmann Irene, Tüscher Oliver
AI Summary
This study found systemic selective beta-blocker changes significantly impact IOP. Clinically, routinely ask patients about systemic medication changes to better manage glaucoma.
Abstract
Purpose
The purpose of this study was to investigate the relationship between the change in systemic medication and intraocular pressure (IOP) on a population-based level.
Methods
The Gutenberg Health Study is a population-based prospective observational cohort study in Germany. As part of the baseline examination (2007-2012) and 5-year follow-up examination (2012-2017), IOP was measured by non-contact tonometry. Systemic medication was recorded at both time points. Multivariable regression analyses were carried out to analyze associations. Moreover, we calculated the dose-response relationship for the dosage change of selective beta-blockers with IOP change over 5 years.
Results
The analysis population included 19,161 eyes of 9633 participants. IOP change was lower in participants with new intake of selective beta-blockers (-0.31 mm Hg, P < 0.001) and increased in those with discontinuation of selective beta-blocker intake (+0.28 mm Hg, P = 0.02). Associations between IOP change and statins and calcium channel blockers (CCBs) could be attributed to co-medications. There was a dose-response relationship for change in selective beta-blocker intake and change in IOP (-0.16 mm Hg/100 mg, P = 0.02).
Conclusions
Use of systemic selective beta-blockers is associated with an IOP change on a population level, whereas the association with other systemic medications on IOP change could be explained by co-medication use or change in blood pressure. Patients undergoing IOP monitoring and management should routinely be asked about changes in systemic medications.
MeSH Terms
Shields Classification
Key Concepts5
The change in intraocular pressure (IOP) was lower by -0.31 mm Hg (P < 0.001) in participants with new intake of systemic selective beta-blockers, based on a population-based prospective observational cohort study in Germany.
The change in intraocular pressure (IOP) increased by +0.28 mm Hg (P = 0.02) in participants who discontinued systemic selective beta-blocker intake, based on a population-based prospective observational cohort study in Germany.
There was a dose-response relationship for the change in systemic selective beta-blocker intake and change in intraocular pressure (IOP) of -0.16 mm Hg/100 mg (P = 0.02) over 5 years, in a population-based prospective observational cohort study in Germany.
Associations between intraocular pressure (IOP) change and systemic statins and calcium channel blockers (CCBs) could be attributed to co-medications, in a population-based prospective observational cohort study in Germany.
The Gutenberg Health Study is a population-based prospective observational cohort study in Germany that collected intraocular pressure (IOP) measurements by non-contact tonometry and systemic medication at baseline (2007-2012) and 5-year follow-up (2012-2017).
Related Articles5
Association of Systemic Medication Use with Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium.
Meta-AnalysisA Systematic Review and Meta-analysis of Systemic Antihypertensive Medications With Intraocular Pressure and Glaucoma.
Systematic ReviewRisk of Intraocular Pressure Increase With Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors: A Cohort Study.
Cohort StudyEffect of Glucosamine on Intraocular Pressure and Risk of Developing Glaucoma.
Observational StudyAssociation Between Medication-Taking and Refractive Error in a Large General Population-Based Cohort.
Cohort StudyIs this article assigned to the wrong chapter(s)? Let us know.